Raffi Asadorian
2022 - AcelRx Pharmaceuticals
In 2022, Raffi Asadorian earned a total compensation of $755.1K as Chief Financial Officer at AcelRx Pharmaceuticals, a 26% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $150,870 |
|---|---|
| Option Awards | $70,463 |
| Salary | $474,435 |
| Stock Awards | $47,176 |
| Other | $12,200 |
| Total | $755,144 |
Asadorian received $474.4K in salary, accounting for 63% of the total pay in 2022.
Asadorian also received $150.9K in non-equity incentive plan, $70.5K in option awards, $47.2K in stock awards and $12.2K in other compensation.
Rankings
In 2022, Raffi Asadorian's compensation ranked 3,617th out of 5,736 executives tracked by ExecPay. In other words, Asadorian earned more than 36.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,617 out of 5,736 | 37th |
Division Manufacturing | 2,058 out of 3,125 | 34th |
Major group Chemicals And Allied Products | 989 out of 1,416 | 30th |
Industry group Drugs | 926 out of 1,317 | 30th |
Industry Pharmaceutical Preparations | 674 out of 963 | 30th |
Source: SEC filing on August 28, 2023.
Asadorian's colleagues
We found two more compensation records of executives who worked with Raffi Asadorian at AcelRx Pharmaceuticals in 2022.
News
AcelRx Pharmaceuticals CEO Vincent Angotti's 2023 pay slips 7% to $1.2M
April 29, 2024
AcelRx Pharmaceuticals CEO Vincent Angotti's 2022 pay falls 47% to $1.3M
August 28, 2023
AcelRx Pharmaceuticals CEO Vincent Angotti's 2021 pay jumps 39% to $2.4M
June 3, 2022
AcelRx Pharmaceuticals CEO Vincent Angotti's 2019 pay jumps 22% to $2.1M
April 24, 2020
AcelRx Pharmaceuticals CEO Vincent Angotti's 2018 pay falls 26% to $1.7M
May 14, 2019